KRAS mutation is predictive of worse results after metastasectomy or adjuvant chemotherapy with hepatic arterial infusion (HAI) pump in the treatment of liver metastases in colorectal cancer patients. However, the KRAS mutation effect on tumor […]
Although trimodal therapy (neoadjuvant chemoradiation therapy followed by surgery) is the current standard, the risk of relapse is high, especially for 70% to 75% of patients who do not […]